CARA looks forward to reporting topline data from our second global Phase 3 trial, KALM-2, in the second half of this year.
Read More
The INSPIRE trial will assess the safety, tolerability and efficacy of Zygel (ZYN002 CBD gel) for the treatment of behavioral symptoms of 22q11.2 Deletion Syndrome (22q).
Read More
The specific way endocannabinoids work is quite complex, but in general terms it can be thought of as a biological thermostat, ensuring that the different tissues and organs throughout the body are working together and within appropriate ranges.
Read More
This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.
Read More
Advances in drug delivery are critical to improving cannabis-based products.
Read More
Get stock alerts, news & related alerts straight to your inbox!